Design and evaluation of chitosan nanoparticles as novel drug carrier for the delivery of rivastigmine to treat Alzheimer's disease

Therapeutic Delivery

Volumn 2, Issue 5, 2011, Pages 599-609

  Wilson, Barnabas ^a   Samanta, Malay K ^b   Muthu, Madaswamy S ^c   Vinothapooshan, Ganesan ^d  

^a Dayananda Sagar University   (India)

^b JSS COLLEGE OF PHARMACY   (India)

^c BANARAS HINDU UNIVERSITY   (India)

^d ARULMIGU KALASALINGAM COLLEGE OF PHARMACY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CHITOSAN; NANOPARTICLE; POLYSORBATE 80; RIVASTIGMINE;

ADULT ANIMAL; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DIFFUSION; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; DRUG TISSUE LEVEL; EMULSION; IN VITRO STUDY; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; SURFACE CHARGE; ZETA POTENTIAL;

EID: 79956155983     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.11.21     Document Type: Article

References (58)

1. Gref R, Minamitake Y, Perracchia MT, Trubeskoy V, Torchilin V, Langer R. Biodegradable long-circulating polymeric nanospheres. Science 263, 1600-1603 (1994). (Pubitemid 24128361)
2. Garcia-Garcia E, Andrieux K, Gil S, Couvreur P. Colloidal carriers and blood-brain barrier (BBB) translocation. A way to deliver drugs to the brain. Int. J. Pharm. 298, 274-292 (2005). (Pubitemid 40910731)
3. Kreuter J, Speiser PP. In-vitro studies of poly(methylmethacrylate) adjuvants. J. Pharm. Sci. 65, 1624-1627 (1976).
4. Kreuter J. Nanoparticle-based drug delivery systems. J. Control. Release 16, 169-176. (1991).
5. Hans ML, Lowman AM. Biodegradable nanoparticles for drug delivery and targeting. Curr. Opin. Solid State Mater. Sci. 6, 319-327 (2002). (Pubitemid 36238389)
6. Mitra S, Gaur U, Ghosh PC, Maitra AN. Tumour targeted delivery of encapsulated dextran-doxorubicin conjugate using chitosan nanoparticles as carrier. J. Control. Release 74, 317-323 (2001). (Pubitemid 32727639)
7. Jain SK, Gupta Y, Jain A et al. Mannosylated gelatin nanoparticles bearing an anti-HIV drug didanosine for site-specific delivery. Nanomed. Nanotech. Biol. Med. 4, 41-48, (2008). (Pubitemid 351324205)
8. Roney C, Kulkarni P, Arora V et al. Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease. J. Control. Release. 108, 193-214 (2005). (Pubitemid 41608654)
9. Kulkarni P, Roney C, Antich P et al. Quinoline-n butylcyanoacrylate-based nanoparticles for brain targeting for the diagnosis of Alzheimer's disease. Rev. Nanomed. Nanotechnol. 2, 35-47 (2010).
10. Allemann E, Gurny R, Deolker E. Drug loaded nanoparticles - preparation methods and drug targeting issues. Eur. J. Pharm. Biopharm. 39, 173-191 (1993). (Pubitemid 23361352)
11. Gaur U, Sahoo SK, De TK, Ghosh PC, Maitra AN, Ghosh PK. Biodistribution of fluoresceinated dextran using novel nanoparticles evading reticuloendothelial system. Int. J. Pharm. 202, 1-10 (2000). (Pubitemid 30466224)
12. Jia Z, Yujun W, Guangsheng L. Adsorption of diuretic furosemide onto chitosan nanoparticles prepared with a water-in-oil nanoemulsion system. React. Funct. Polym. 65, 249-257 (2005).
13. Chandy T, Sharma CP. Chitosan as a biomaterial. Biomater. Artif. Cells Artif. Org. 18, 1-24 (1990).
14. Qi L, Xu Z, Jiang X, Hu C, Zou X. Preparation and antibacterial activity of chitosan nanoparticles. Carbohyd. Res. 339, 2693-2700 (2004). (Pubitemid 39425140)
15. Felt O, Buri P, Gurny R. Chitosan. a unique polysaccharide for drug delivery. Drug Dev. Ind. Pharm. 24, 979-993 (1998). (Pubitemid 28460237)
16. Arai K, Kinumaki T, Fujita T. Toxicity of chitosan. Bull. Tokai Reg. Fish Lab. 43, 89-94 (1968).
17. Nicol S. Life after death for empty shells. New Sci. 129, 46-48 (1991).
18. Qi L, Xu Z, Chen M. In vitro and in vivo suppression of hepatocellular carcinoma growth by chitosan nanoparticles. Eur. J. Cancer 3, 184-193 (2007). (Pubitemid 46054473)
19. Calvo P, Remunan-Lopez C, Vila-Jato LJ, Alonso MJ. Chitosan and chitosan/ethylene oxide-propylene oxide block copolymer nanoparticles as novel carriers for proteins and vaccines. Pharm. Res. 14, 1431-1436 (1997). (Pubitemid 27481075)
20. Tokumitsu H, Ichikawa H, Fukumori Y. Chitosan-gadopentetic acid complex nanoparticles for gadolinium neutron-capture therapy of cancer: Preparation by novel emulsion-droplet coalescence technique and characterization. Pharm. Res. 16, 1830-1835 (1999). (Pubitemid 30040698)
21. Berthold A, Cremer K, Kreuter J. Preparation and characterization of chitosan microspheres as drug carrier for prednisolone sodium phosphate as model for anti-inflammatory drugs. J. Control. Release 39, 17-25 (1996). (Pubitemid 26139808)
22. Niwa T, Takeuchi H, Hino T, Kunou N, Kawashima Y. Preparation of biodegradable nanospheres of water soluble and insoluble drugs with d,l-lactide/glycolide copolymer by a novel spontaneous emulsification solvent diffusion method, and the drug release behavior. J. Control. Release 25, 89-98 (1993). (Pubitemid 23168633)
23. Mitra S, Gaur U, Ghosh PC, Maitra AN. Tumor targeted delivery of encapsulated dextran-doxorubicin conjugate using chitosan nanoparticles as carrier. J. Control. Release 74, 317-323 (2001). (Pubitemid 32727639)
24. Autuono P, Beyer J. The burden of dementia. A medical and research perspective. Theor. Med. Bioeth. 20, 3-13 (1999). (Pubitemid 29276924)
25. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer's disease. Alzheimer's Dement. 3, 186-191 (2007). (Pubitemid 46825511)
26. Small GW, Rabins PV, Barry PP et al. Consensus statement of the American Association of Geriatric Psychiatry, the Alzheimer's association and the American Geriatric Society. JAMA 278, 1363-1371 (1997).
27. Gao S, Hendrie HC, Hall KS, Hui S. The relationship between age, sex, and the incidence of dementia and Alzheimer's disease. a meta-analysis. Arch. Gen. Psychiatry 55, 809-815 (1998).
28. Tariot PN, Farlow MR, Grossberg GT et al. Memantine treatment in patients with moderate to severe Alzheimer's disease aready reciving donepezil: A randomized controlled trial. JAMA 291, 317-324 (2004). (Pubitemid 38101604)
29. Williams BR, Nazarians A, Gill MA. A review of Rivastigmine. A reversible cholinesterase inhibitor. Clin. Ther. 25, 1634-1653 (2003). (Pubitemid 36801939)
30. Ballard CG. Advances in the treatment of Alzheimer's disease. benefits of dual cholinesterase inhibition. Eur. J. Neurol. 47, 64-70 (2002).
31. Wilson B, Samanta MK, Santhi K, Sampathkumar KP, Ramasamy M, Suresh B. Chitosan nanoparticles as a novel delivery system for anti-Alzheimer's drug tacrine. Nanomed. Nanotech. Biol. Med. 6, 144-152 (2010).
32. Kreuter J, Ramge P, Petrov V et al. Direct evidence that Polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanism requiring prior binding of drugs to the nanoparticles. Pharm. Res. 20, 409-416 (2003). (Pubitemid 36288370)
33. Costa P, Lobo JMS. Modeling and comparison of dissolution profiles. Eur. J. Pharm. Sci. 13, 123-133 (2001). (Pubitemid 32288781)
34. Zhang Z, Liao G, Nagai T, Hou S. Mitoxantrone polybutyl cyanoacrylate nanoparticles as an anti-neoplastic targeting drug delivery system. Int. J. Pharm. 139, 1-8 (1996). (Pubitemid 26276261)
35. Lazartigues E, Freslon J-L, Tellioglu T et al. Pressor and bradycardic effects of tacrine and other acetylcholinesterase inhibitors in the rat. Eur. J. Pharmacol. 361, 61-71 (1998). (Pubitemid 28522159)
36. Löbenberg R, Araujo L, von Brisen H, Rodgers E, Kreuter J. Body distribution of azidothymidine bound to hexyl-cyanoacrylate nanoparticles after i.v. injection to rats. J. Control. Release 50, 21-30 (1998). (Pubitemid 28044097)
37. Pop E, Prókai-Tátrai K, Scott JD, Brewster ME, Bodor N. Application of a brain-targeting chemical delivery system to 9-amino-1,2,3,4-tetrahydroacridine. Pharm. Res. 7, 658-664 (1990). (Pubitemid 20286536)
38. El-Shabouri MH. Positively charged nanoparticles for improving the oral bioavailability of cyclosporin-A. Int. J. Pharm. 249, 101-108 (2002). (Pubitemid 35333436)
39. Gao K, Jiang X. Influence of particle size on transport of Methotrexate across blood-brain barrier by polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Int. J. Pharm. 310, 213-219 (2006). (Pubitemid 43287986)
40. Banerjee T, Mitra S, Singh AK, Sharma RK, Maitra A. Preparation and biodistribution of ultrafine chitosan nanoparticles. Int. J. Pharm. 243, 93-105 (2002).
41. Quellec P, Gref R, Perrin L et al. Protein encapsulation within polyethylene glycol-coated nanospheres. I. Physicochemical characterization. J. Biomed. Materi. Res. 42, 45-54 (1998). (Pubitemid 28412996)
42. Ganza-Gonzalez A, Auguiano-Igea S, Otero-Espinar FJ, Mendez JB. Chitosan and chondroitin microsphere for oral administration controlled release of metoclopramine. Eur. J. Pharm. Biopharm. 48, 149-155 (1999). (Pubitemid 29401991)
43. Kulkarni GT, Gowthamrajan K, Suresh B. Stability testing of pharmaceutical products. An overview. Ind. J. Pharm. Edu. 38, 194-202 (2004).
44. Jain SK, Gupta Y, Jain A, Saxena AR, Khare P, Jain A. Mannosylated gelatin nanoparticles bearing an anti-HIV drug didanosine for site-specific delivery. Nanomed. Nanotech. Biol. Med. 4, 41-48 (2008). (Pubitemid 351324205)
45. Illum L, Davis SS, Wilson CG, Frier M, Hardy JG, Thomas NW. Blood clearance and organ deposition of intravenously administered colloidal particles. the effects of particle size, nature and shape. Int. J. Pharm. 12, 135-146 (1982). (Pubitemid 12037337)
46. Chiannilkulchai N, Ammoury N, Caillou B, Devissageut J, Couvreur P. Hepatic tissue distribution of doxorubicin loaded nanoparticles after i.v. administration in reticulosarcoma M 5076 metastases-bearing mice. Cancer Chemother. Pharmacol. 26, 122-126 (1990). (Pubitemid 20153803)
47. Gulyaev AE, Gelperina SE, Skidan IN, Antropov AS, Ya G, Kreuter J. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm. Res. 16, 1564-1569 (1999). (Pubitemid 29510553)
48. Schroeder U, Schroeder H, Sabel BA. Body distribution of 3H-labelled dalargin bound to poly(butylcyanoacrylate) nanoparticles after i.v. injections to mice. Life Sci. 66, 495-502 (2000). (Pubitemid 30062922)
49. Reddy LH, Murthy RSR. Pharmacokinetics and biodistribution studies of doxorubicin loaded poly(butylcyanoacrylate) nanoparticles synthesized by two different techniques. Biomed. Papers 148, 161-166 (2004).
50. Wilson B. Brain targeting PBCA nanoparticles and the blood-brain barrier. Nanomedicine 4, 499-502 (2009).
51. Wolberg H, Lippoldt A. Tight junctions of the blood-brain barrier: Development, composition and regulation. Vas. Pharmacol. 38, 323-337 (2002). (Pubitemid 36398254)
52. Stewart PA, Tuor UI. Blood-eye barriers in the rat. correlation of ultrastructure with function. J. Comp. Neurol. 340, 566-576 (1994). (Pubitemid 24045566)
53. Bodor N, Buchwald P. Recent advances in the brain targeting of neuropharmaceuticals by chemical delivery systems. Adv. Drug Deliv. Rev. 36, 229-254 (1999). (Pubitemid 29121974)
54. Terasaki T, Hosoya K. The blood-brain barrier efflux transporters as a detoxifying system for the brain. Adv. Drug Deliv. Rev. 36, 195-209 (1999). (Pubitemid 29121972)
55. Kreuter J. Nanoparticle systems for brain delivery of drugs. Adv. Drug Deliv. Rev. 47, 65-81 (2001). (Pubitemid 32209233)
56. Wilson B, Samanta MK, Santhi K, Sampathkumar KP, Paramakrishnan N, Suresh B. Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease. Brain Res. 1200, 159-168 (2008).
57. Wilson B, Samanta MK, Santhi K, Sampathkumar KP, Paramakrishnan N, Suresh B. Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles. Eur. J. Pharm. Biopharm. 70, 75-84 (2008).
58. Friese A, Seiller E, Quack G, Lorenz B, Kreuter J. Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacrylate) nanoparticles as a parenteral controlled release system. Eur. J. Pharm. Biopharm. 49, 103-109 (2000). (Pubitemid 30126057)